These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21455225)

  • 1. Deal watch: Aveo and Astellas to develop VEGF inhibitor for renal cell carcinoma.
    Nat Rev Drug Discov; 2011 Apr; 10(4):248. PubMed ID: 21455225
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):512-3. PubMed ID: 26351813
    [No Abstract]   [Full Text] [Related]  

  • 3. Tivozanib in renal cell carcinoma.
    Figlin R
    Clin Adv Hematol Oncol; 2013 Jan; 11(1):43-5. PubMed ID: 23416862
    [No Abstract]   [Full Text] [Related]  

  • 4. Tivozanib: a new treatment option for renal cell carcinoma.
    Saes L; Eskens FALM
    Drugs Today (Barc); 2017 Nov; 53(11):609-618. PubMed ID: 29451277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
    Zahoor H; Rini BI
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for survival in metastatic renal cell carcinoma: update 2008.
    Bukowski RM
    Cancer; 2009 May; 115(10 Suppl):2273-81. PubMed ID: 19402065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib for the treatment of renal cell carcinoma.
    Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
    Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New targets and drugs for treatment of advanced renal cell carcinoma].
    Rohde D
    Aktuelle Urol; 2005 Apr; 36(2):125-30. PubMed ID: 15902572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecularly targeted agents for renal cell carcinoma: the next generation.
    Cowey CL; Hutson TE
    Clin Adv Hematol Oncol; 2010 May; 8(5):357-60, 361-4. PubMed ID: 20551895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
    Rini BI; Flaherty K
    Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for renal cell carcinoma.
    Varella L; Rini BI
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):343-53. PubMed ID: 20443750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tivozanib: practical implications for renal cell carcinoma and other solid tumors.
    Berge EM; Bowles DW; Flaig TW; Lam ET; Jimeno A
    Drugs Today (Barc); 2013 May; 49(5):303-15. PubMed ID: 23724410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).
    Haberkorn BC; Eskens FA
    Future Oncol; 2013 Jan; 9(1):13-20. PubMed ID: 23252559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug now immediately available in Germany].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):18-9. PubMed ID: 23646396
    [No Abstract]   [Full Text] [Related]  

  • 15. The end of chemotherapy in renal cell carcinoma: for much but not for all.
    Iacovelli R; Raimondi C; Palazzo A
    Am J Clin Oncol; 2010 Oct; 33(5):522-3. PubMed ID: 20924226
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecularly targeted therapies for renal cell cancer: TRAIL research advances.
    Buttyan R; Mian BM
    J Urol; 2007 May; 177(5):1606. PubMed ID: 17437767
    [No Abstract]   [Full Text] [Related]  

  • 17. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
    Flaherty KT; Puzanov I
    Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination targeted therapy in advanced renal cell carcinoma.
    Sosman J; Puzanov I
    Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.
    Shepard DR; Garcia JA
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):795-805. PubMed ID: 19496716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
    Mulders P
    BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.